Avelumab binds PD-L1 on target cells and, via its IgG1 Fc, engages Fcγ receptor–bearing effector cells (e.g., NK cells) to trigger ADCC that kills PD-L1–expressing cells; checkpoint blockade also indirectly enhances T-cell killing.